<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-99465" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Primary Bone Cancer</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pullan</surname>
            <given-names>Jack E.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lotfollahzadeh</surname>
            <given-names>Saran</given-names>
          </name>
          <aff>Vascular Reserach, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA, Department of Surgery, vascular and endovascular surgery section, Boston Medical Center, Boston, MA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jack Pullan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Saran Lotfollahzadeh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-99465.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Primary bone cancer emerges as an uncommon malignant tumor originating from primitive mesenchymal cells within the bone. With distinctive subtypes such as osteosarcoma, chondrosarcoma, and Ewing sarcoma, each presents unique demographics, imaging traits, and biological attributes. Surgical excision, complemented by chemotherapy and radiotherapy, constitutes the primary treatment approach, demanding a nuanced understanding from clinicians for accurate diagnosis and informed treatment strategies.</p>
        <p>In this activity, participants explore primary bone cancer assessment and treatment, emphasizing the interprofessional team's indispensable role. Comprising experts from radiology, histopathology, oncology, and orthopedics, this team collaborates to devise a comprehensive care plan. Additionally, the holistic team includes physiotherapists, occupational therapists, prosthetists, dieticians, social workers, and counselors, offering comprehensive support throughout the patient's journey. Through collaborative efforts, clinicians enhance their competence in managing primary bone cancer, ensuring optimal patient outcomes and quality of care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate primary bone cancer from other musculoskeletal conditions and secondary bone cancers.</p></list-item><list-item><p>Assess the&#x000a0;pertinence of laboratory tests and imaging modalities when diagnosing primary bone cancer.</p></list-item><list-item><p>Determine&#x000a0;the appropriate management of primary bone cancer in a stepwise treatment plan.</p></list-item><list-item><p>Implement care coordination&#x000a0;within an interprofessional team to manage patients with primary bone cancer.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=99465&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=99465">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-99465.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Primary bone cancer is a rare malignant tumor of the bone originating from primitive mesenchymal cells. This condition accounts for around 0.2% of all malignancies worldwide and is idiopathic in most cases. Multiple subtypes are prevalent, with osteosarcoma, chondrosarcoma, and Ewing sarcoma being the most common. Each varies in demographics, imaging appearance, and biological behavior. They are frequently aggressive and require early diagnosis, utilizing imaging and tissue biopsy. Surgical excision remains the mainstay of curative treatment, with chemotherapy and radiotherapy used in conjunction.<xref ref-type="bibr" rid="article-99465.r1">[1]</xref></p>
      </sec>
      <sec id="article-99465.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Though&#x000a0;primary bone cancer&#x000a0;is most often idiopathic, risk factors also play a role in developing this cancer.</p>
        <list list-type="bullet">
          <list-item>
            <p>Genetic factors are linked. Germline abnormalities in hereditary cancer predisposition syndromes have an increased risk of later developing bone cancer through the downregulation of tumor suppressor genes or upregulation of oncogenes. The TP53 tumor suppressor gene is often altered in Li-Fraumeni syndrome, putting patients at an increased risk of developing osteosarcoma. Similarly, a mutation in the Rb1 gene leading to hereditary retinoblastoma is linked to osteosarcoma. Werner and Rothmund-Thomson syndromes are also linked to an increased risk of developing osteosarcoma.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Previous treatment for cancer with radiotherapy is linked to an increased risk of developing&#x000a0;primary bone cancer in later life, particularly when exposed to ionizing radiation in childhood.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Several benign conditions show the potential to progress to primary bone cancer. Paget disease of the bone is a condition characterized by a disorder of bone metabolism, particularly osteoclastic function. These patients are at an increased risk of developing osteosarcoma; however, it is a rare complication. Enchondromas and osteochondromas are benign cartilaginous neoplasms that can later develop into malignant chondrosarcoma.<xref ref-type="bibr" rid="article-99465.r2">[2]</xref><xref ref-type="bibr" rid="article-99465.r3">[3]</xref><xref ref-type="bibr" rid="article-99465.r4">[4]</xref><xref ref-type="bibr" rid="article-99465.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-99465.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Primary bone cancer remains uncommon, accounting for 0.2% of all malignancies and 5% of childhood malignancies. In the United States, an estimated 3600 new cases of&#x000a0;primary bone cancer&#x000a0;were diagnosed in 2020, with 1720 deaths, making up 0.3% of all cancer deaths. The National Cancer Institute data shows that chondrosarcoma (40%) is most prevalent in adults, followed by osteosarcoma (28%). In children and adolescents, osteosarcoma (56%) is the most common, with Ewing sarcoma (34%) second. Chordoma, undifferentiated pleomorphic sarcoma, adamantinoma, fibrosarcoma, and giant cell tumor of the bone are also types of primary bone cancer; however, they are fewer in number. Primary bone cancer&#x000a0;has a male predominance, with a worldwide osteosarcoma male-to-female ratio of 1.43&#x000a0;to 1.<xref ref-type="bibr" rid="article-99465.r6">[6]</xref><xref ref-type="bibr" rid="article-99465.r7">[7]</xref></p>
      </sec>
      <sec id="article-99465.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Primary bone cancer is a malignant tumor of the connective tissue with mesenchymal origin. The World Health Organisation determined 6 categories: chondrogenic, osteogenic, notochordal, vascular, other malignant mesenchymal, and miscellaneous (including Ewing sarcoma). The pathophysiology varies considerably between groups and, in some cases, is poorly understood.<xref ref-type="bibr" rid="article-99465.r6">[6]</xref></p>
        <p>Osteosarcoma is a highly malignant osteogenic tumor that can develop in any bone. The tumor tends to develop near the metaphysis of long bones in young patients. The most common sites are the distal femur, proximal tibia, and proximal humerus, with high bone turnover. In adults, the axial skeleton is more common, where previous irradiation or metabolic disease of the bone is often associated. Common genetic changes are not present to explain the growth of this tumor type; however, 70% of cases demonstrate some level of chromosomal abnormality. Alterations in p53, Rb1, and deoxyribonucleic acid repair/surveillance genes are present in patients with Li-Fraumeni, Bloom, and Rothmund-Thomson syndrome, all linked to increased rates of osteosarcoma.<xref ref-type="bibr" rid="article-99465.r8">[8]</xref><xref ref-type="bibr" rid="article-99465.r9">[9]</xref><xref ref-type="bibr" rid="article-99465.r10">[10]</xref></p>
        <p>Chondrosarcoma is primarily a disease of adults, most frequently diagnosed in patients between 30 and 60. They are generally slow-growing chondrogenic tumors of intermediate malignancy, rarely metastasizing. Chondrosarcoma arising de novo are classified as primary (&#x0003e;85% of cases), with those arising from pre-existing benign osteochondromas or enchondromas as secondary. The most common site for diagnosis is the long bones of the appendicular skeleton. Flat bones, including the pelvis, ribs, and scapula, can also be affected. The exact pathogenesis of chondrosarcoma is unknown, though multiple genes are implicated. Cytogenic studies have identified structural and numerical chromosomal abnormalities. Gene mutations in&#x000a0;<italic toggle="yes">EXT1/2,</italic>&#x000a0;<italic toggle="yes">TP53</italic>,&#x000a0;<italic toggle="yes">Rb1</italic>, and&#x000a0;<italic toggle="yes">IDH1/2&#x000a0;</italic>have also been linked to malignant transformation in benign lesions.<xref ref-type="bibr" rid="article-99465.r5">[5]</xref><xref ref-type="bibr" rid="article-99465.r11">[11]</xref></p>
        <p>Ewing sarcoma is an aggressive tumor of childhood and adolescence, most commonly occurring in the bone but also seen in soft tissues. The peak incidence is at 15 years, and the men-to-women ratio is 5:1. The most frequent sites involved are long bones in the lower limb, pelvic bones, and the axial skeleton (ribs and vertebral column). Ewing sarcoma develops characteristically at the diaphysis, in contrast to the pattern seen in osteosarcoma. Ewing sarcoma is genetically well described, with characteristic chromosomal translocations identified. The translocation leads to fusing an FET protein to an ETS transcription factor, most commonly&#x000a0;<italic toggle="yes">FLI1&#x000a0;</italic>(&#x0003e;85% of cases). The result is the formation of fusion proteins that deregulate downstream genes, altering cell behavior.<xref ref-type="bibr" rid="article-99465.r12">[12]</xref><xref ref-type="bibr" rid="article-99465.r13">[13]</xref><xref ref-type="bibr" rid="article-99465.r14">[14]</xref></p>
      </sec>
      <sec id="article-99465.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Diagnosis of primary bone cancer requires a tissue biopsy to perform histopathological assessment, with significant heterogeneity seen.</p>
        <p>
<bold>Osteosarcoma</bold>
</p>
        <p>The formation of bone or osteoid characterizes osteosarcoma, and this identification is key to diagnosis. Several histological subtypes have been identified, determined by the tumor's bone location and grade.<xref ref-type="bibr" rid="article-99465.r15">[15]</xref><xref ref-type="bibr" rid="article-99465.r8">[8]</xref></p>
        <p>
<bold>Intramedullary:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Conventional</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Most prevalent subtype, comprising 80% of all osteosarcomas</p>
              </list-item>
              <list-item>
                <p>Classically high-grade, arising from the intramedullary canal</p>
              </list-item>
              <list-item>
                <p>Spindle to polyhedral cell shape malignant mesenchymal cells are seen</p>
              </list-item>
              <list-item>
                <p>Cell nuclei are pleomorphic with occasional mitotic figures</p>
              </list-item>
              <list-item>
                <p>Extracellular matrix production can be osteoblastic, osteoclastic, or fibroblastic; a combination is common</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>Telangiectatic</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p><bold>&#x000a0;</bold>&#x0003c;4% of osteosarcomas</p>
              </list-item>
              <list-item>
                <p>&#x000a0;Dilated hemorrhagic sinusoids seen with small amounts of osteoid&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Cavities mimic the appearance of an aneurysmal bone cyst, with the presence of high-grade sarcoma cells distinguishing the tumor</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>Low-grade</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>&#x0003c;2% of osteosarcomas</p>
              </list-item>
              <list-item>
                <p>Well-differentiated cells embedded in the osseous matrix and fibrous stroma, with small amounts of osteoid</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>Small cell</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>1.5% of osteosarcomas</p>
              </list-item>
              <list-item>
                <p>Numerous small round malignant cells seen within an osteoid matrix.&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Small cell sarcoma can resemble Ewing sarcoma; production of osteoid and sporadic spindling of cells are distinguishing features&#x000a0;<xref ref-type="bibr" rid="article-99465.r15">[15]</xref><xref ref-type="bibr" rid="article-99465.r8">[8]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Surface:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Parosteal&#x000a0;</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>1% to 6% of osteosarcomas</p>
              </list-item>
              <list-item>
                <p>Slow growing, arising from the outer surface of the metaphysis&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Low-grade, with a well-differentiated, mostly cartilaginous matrix with minimal osteoid</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>Periosteal</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>1% to 2% of osteosarcomas&#x000a0;</p>
              </list-item>
              <list-item>
                <p>More aggressive than parosteal osteosarcoma, with intermediate-grade tumors showing increased cell atypia&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Mostly cartilaginous matrix with minimal osteoid</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>High-grade</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p><bold>&#x000a0;</bold>&#x0003c;1% of osteosarcomas&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Histologically similar to conventional osteosarcoma, showing high-grade spindle-shaped cells with nuclear pleomorphism&#x000a0;<xref ref-type="bibr" rid="article-99465.r15">[15]</xref><xref ref-type="bibr" rid="article-99465.r8">[8]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Chondrosarcoma</bold>
</p>
        <p>The production of hyaline cartilage characterizes chondrosarcomas to form a cartilaginous matrix. Lobules of cartilage are seen with significant variation in dimension. Cell nuclei show pleomorphism with chondrocytes varying in size and shape. Conventional chondrosarcoma accounts for over 85% of all chondrosarcomas. Chondrosarcoma can be subcategorized into primary central (developing within the medullary canal) or secondary peripheral (developing from the surface of the bone secondary to pre-existing enchondroma or osteochondroma). Histologically, both primary central and secondary peripheral are alike. Grading is an essential process that allows for the prediction of clinical behavior.<xref ref-type="bibr" rid="article-99465.r5">[5]</xref><xref ref-type="bibr" rid="article-99465.r16">[16]</xref><xref ref-type="bibr" rid="article-99465.r17">[17]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Grade I:&#x000a0;</bold>These are low-grade, lowly cellular lesions with a predominantly cartilaginous matrix and small, dense nuclei. Distinguishing grade I chondrosarcoma and benign enchondroma can be difficult, both radiologically and histologically.</p>
          </list-item>
          <list-item>
            <p><bold>Grade II:&#x000a0;</bold>This shows a reduced cartilaginous matrix and moderately cellular. Nuclei are enlarged and hyperchromatic, with increased atypia. Mitoses may be seen.</p>
          </list-item>
          <list-item>
            <p><bold>Grade III:&#x000a0;</bold>These are high-grade lesions that are highly cellular, with increased cellular atypia showing vesicular and enlarged nuclei. Cartilaginous matrix is rare or absent, with myxoid material evident, and mitoses are more readily identified.</p>
          </list-item>
        </list>
        <p>Several rare subtypes of chondrosarcoma are also identified. De-differentiated chondrosarcoma is characterized by low-grade chondrosarcoma next to a de-differentiated high-grade lesion, with a sharp transition between the 2. The tumor is extremely aggressive. Mesenchymal chondrosarcoma is a high-grade tumor occurring in either bone or soft tissue. Undifferentiated small round cells are seen with varying amounts of a cartilaginous matrix. Clear cell chondrosarcoma is a low-grade tumor, with cells showing clear, vacuolated cytoplasm. Areas of hemorrhage and cyst formation are seen.<xref ref-type="bibr" rid="article-99465.r5">[5]</xref></p>
        <p>
<bold>Ewing Sarcoma</bold>
</p>
        <p>Ewing sarcoma is a high-grade aggressive sarcoma and belongs to the group of small round-cell tumors. Monomorphic small cells are seen in sheets, with round nuclei, finely dispersed chromatin, and nucleoli usually unidentifiable. Frequently, necrosis is seen, with remaining viable cells arranged perivascularly. Cell membranes express the glycoprotein CD99, with immunohistochemistry showing that &#x0003e;95% of Ewing sarcomas have extensive membranous expression. CD99 expression is not specific to Ewing sarcoma; other markers are also used for diagnosis.<xref ref-type="bibr" rid="article-99465.r18">[18]</xref><xref ref-type="bibr" rid="article-99465.r14">[14]</xref></p>
        <p>
<bold>Other Types of Primary Bone Cancer</bold>
</p>
        <p>Chordoma, adamantinoma, and giant cell tumors of bone are typically low-grade locally invasive tumors. Undifferentiated pleomorphic sarcoma and fibrosarcoma are aggressive malignant tumors with a generally poor prognosis.<xref ref-type="bibr" rid="article-99465.r19">[19]</xref><xref ref-type="bibr" rid="article-99465.r20">[20]</xref></p>
      </sec>
      <sec id="article-99465.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Primary bone cancer is a rare diagnosis, with primary care clinicians unlikely to encounter a single case. Early diagnosis improves overall survival; however, delays remain common. History and examination form the first steps in diagnosing primary bone cancer, and an urgent referral to a specialist center is needed for all patients with a possible diagnosis.<xref ref-type="bibr" rid="article-99465.r12">[12]</xref><xref ref-type="bibr" rid="article-99465.r6">[6]</xref></p>
        <p>Pain is the most common symptom, described as deep-seated dull pain progressing over time, refractory to simple analgesia. Pain can be troublesome at night, which is always a red flag. A mass may be palpable with localized tenderness. Patients may exhibit signs of systemic disease, including lethargy, malaise, and fever; however, in high-grade tumors, these are often not present and may suggest metastatic disease. A pathological fracture can be the first sign; any abnormal fracture requires further investigation. History of predisposing genetic conditions (eg, Li-Fraumeni syndrome, hereditary retinoblastoma, Werner syndrome, and Rothmund-Thomson syndrome) or diseases (Paget disease) is crucial.<xref ref-type="bibr" rid="article-99465.r6">[6]</xref>&#x000a0;Physical examination should focus on pain, tenderness, or mass. The site should be inspected and palpated, with size, consistency, mobility, location of the mass, and overlying skin changes noted. Lymph nodes should be palpated.<xref ref-type="bibr" rid="article-99465.r21">[21]</xref></p>
      </sec>
      <sec id="article-99465.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnostic modalities used in primary bone cancer include imaging, laboratory blood tests, and tissue biopsy.</p>
        <p>
<bold>Plain Film Radiograph</bold>
</p>
        <p>All patients should have orthogonal plain film radiographs when identifying potential bone cancer. Plain x-rays may show the following findings:</p>
        <list list-type="bullet">
          <list-item>
            <p>Osteolytic, osteoblastic, or mixed changes</p>
          </list-item>
          <list-item>
            <p>A moth-eaten appearance (suggests bone destruction secondary to a rapidly expanding tumor within a bone, commonly seen in Ewing sarcoma and telangiectatic osteosarcoma)</p>
          </list-item>
          <list-item>
            <p>A permeative appearance (suggests the tumor progresses through bone, with an ill-defined zone between the tumor and healthy bone, often seen in small cell tumors, including Ewing sarcoma)</p>
          </list-item>
          <list-item>
            <p>"Onion skinning," with the tumor lifting partially-formed periosteal bone (classically seen in Ewing sarcoma)</p>
          </list-item>
          <list-item>
            <p>"Codman triangle," with periosteum lifted off bone and osteoid laid down</p>
          </list-item>
          <list-item>
            <p>"Sunburst" appearance, with vertical osteoid calcification due to significant periostitis&#x000a0;<xref ref-type="bibr" rid="article-99465.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Magnetic Resonance Imaging&#x000a0;</bold>
</p>
        <p>A magnetic resonance imaging, MRI, scan remains the gold standard for assessing local tumor extent. The whole anatomical compartment should be imaged, and the MRI should be sensitive for bone and soft tissue lesions. Biopsy planning is crucial, and MRI allows the definition of neurovascular structures. Modern techniques, including dynamic MRI, better characterize high-grade tumor areas and have been used to assess tumor response to chemotherapy.<xref ref-type="bibr" rid="article-99465.r6">[6]</xref><xref ref-type="bibr" rid="article-99465.r23">[23]</xref></p>
        <p>
<bold>Computed Tomography&#x000a0;</bold>
</p>
        <p>A computed tomography, CT, scan is used when the diagnosis remains unclear following an MRI or if an MRI is contraindicated. CT remains the modality of choice in pelvic bone cancer and reconstructive surgery. Patients with confirmed primary bone cancer require staging, and although many centers still perform chest radiographs, a chest CT scan is the gold standard for assessing metastatic pulmonary disease.<xref ref-type="bibr" rid="article-99465.r6">[6]</xref></p>
        <p>
<bold>Whole-Body Bone Scintigraphy&#x000a0;</bold>
</p>
        <p>A whole-body bone scintigraphy bone scan is a nuclear medicine study that utilizes technetium-99m as an active agent, highlighting areas of osteoblastic activity. It allows the detection of malignancy and is useful in diagnosing metastatic disease.</p>
        <p>
<bold>Positron Emission Tomography&#x000a0;</bold>
</p>
        <p>The positron emission tomography, PET, scan is a nuclear medicine study that utilizes the high metabolic rate of tumor cells, measuring the uptake of injected radiolabeled F-18 fluoro-deoxy-glucose. A PET scan is in some centers for the initial staging of primary bone cancer, and studies have suggested it as a modality for follow-up when used in combination with a CT scan.<xref ref-type="bibr" rid="article-99465.r24">[24]</xref></p>
        <p>
<bold>Laboratory Blood Tests</bold>
</p>
        <p>Specific laboratory blood tests are not used in diagnosing primary bone cancer; however, they form part of the patient workup. In patients treated with chemotherapy, baseline urea, creatinine, and liver function tests allow baseline renal and hepatic function assessment. Biochemical markers alkaline phosphatase and lactate dehydrogenase offer some predictive value, and levels can be monitored in follow-up to assess for disease recurrence.<xref ref-type="bibr" rid="article-99465.r22">[22]</xref></p>
        <p>
<bold>Tissue Biopsy</bold>
</p>
        <p>A lesion biopsy is needed for definitive diagnosis, allowing for histopathological assessment and tumor grading. Biopsy should be performed with the operating surgical team, ideally in a specialist bone cancer center. The procedure requires meticulous planning, with suboptimal biopsy impacting definitive surgical treatment options. Imaging should be performed before a biopsy, aiding in approach planning and preventing tissue disruption that could make radiological assessment more difficult. Percutaneous, incisional, or excisional techniques are used. Ultrasound, x-ray, and CT scans allow precise guidance. The tract should be well marked, allowing for excision during surgery, and a specialist bone cancer pathologist should assess samples. Specific markers on immunohistochemistry staining would assist in the diagnosis. Greater than 95% of Ewing sarcomas show extensive membranous expression of CD99; this is not specific to Ewing sarcoma, so other markers are also used in the immunohistochemistry panel.<xref ref-type="bibr" rid="article-99465.r21">[21]</xref></p>
      </sec>
      <sec id="article-99465.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Managing primary bone cancer requires a multidisciplinary approach by a specialist bone cancer center, including staff trained in providing age-appropriate care to children or adolescents. Management depends on several factors, including tumor type, stage and grade, and patient preference. Surgical excision remains the cornerstone of primary bone cancer treatment. Neoadjuvant and adjuvant chemotherapy are also commonplace in the management, with radiotherapy used in specific cases.</p>
        <p>
<bold>Surgery</bold>
</p>
        <p>Surgical resection aims to remove all tumor tissue with adequate margins while preserving as much limb function as possible. A decision for either limb salvage surgery or amputation is established using imaging, histopathology, response to adjuvant treatment, and patient wishes. Surgery often leads to significant tissue loss, and open discussion with the patient is vital. The surgery's potential risks, benefits, and expected long-term functional impact must be highlighted. Low-grade tumors amenable to surgical excision typically require wide excision (removing the involved part of the bone with a cuff of healthy tissue), with high-grade tumors requiring radical excision (removing the affected bone and associated soft tissues within the anatomical compartment).<xref ref-type="bibr" rid="article-99465.r6">[6]</xref><xref ref-type="bibr" rid="article-99465.r25">[25]</xref></p>
        <p>
<bold>Chemotherapy</bold>
</p>
        <p>Multiple chemotherapy agents and regimens are used to manage primary bone cancer. Often, this consists of induction (neoadjuvant) and postoperative combination therapy (adjuvant), with improvements in rates of limb salvage surgery and overall survival since their introduction. Chemotherapy forms part of the standard treatment protocol for osteosarcoma and Ewing sarcoma. Chondrosarcoma is still primarily managed surgically, except in cases of mesenchymal chondrosarcoma, where chemotherapy and radiotherapy are often used.<xref ref-type="bibr" rid="article-99465.r26">[26]</xref><xref ref-type="bibr" rid="article-99465.r27">[27]</xref></p>
        <p>Neoadjuvant chemotherapy is primarily used to reduce the rate of future metastatic spread; however, study results have suggested it can also contribute to primary tumor control. A good response to neoadjuvant therapy is determined by a histological necrosis rate of less than 90%, with a poor response indicating a change in postoperative adjuvant chemotherapy agents and poorer outcomes.<xref ref-type="bibr" rid="article-99465.r28">[28]</xref><xref ref-type="bibr" rid="article-99465.r29">[29]</xref><xref ref-type="bibr" rid="article-99465.r30">[30]</xref></p>
        <p>
<bold>Radiotherapy</bold>
</p>
        <p>Radiotherapy is often used as adjunctive therapy in primary bone cancer. Ewing sarcoma is a radiosensitive tumor, with radiotherapy commonly used as part of the definitive treatment plan. Preoperative radiotherapy is used if the response to neoadjuvant chemotherapy is poor or the tumor is positioned in a problematic anatomical location, where reduction of tumor volume will aid surgical resection. If sufficient tumor volume cannot be removed surgically or it would be unacceptably disabling, radiotherapy is used for local treatment. Where adequate margins have not been resected, postoperative radiotherapy is utilized. Chondrosarcomas are relatively radioresistant, with radiotherapy only utilized for surgically unresectable or incompletely resected tumors. Radiotherapy has a palliative role in all primary bone cancers and is used to slow tumor growth locally and relieve pain.<xref ref-type="bibr" rid="article-99465.r6">[6]</xref><xref ref-type="bibr" rid="article-99465.r31">[31]</xref><xref ref-type="bibr" rid="article-99465.r32">[32]</xref></p>
      </sec>
      <sec id="article-99465.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of primary bone cancer includes the following:</p>
        <p>
<bold>Malignant&#x000a0;Types of Tumors</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Metastases</p>
          </list-item>
          <list-item>
            <p>Lymphoma</p>
          </list-item>
          <list-item>
            <p>Multiple myeloma</p>
          </list-item>
        </list>
        <p>
<bold>Benign&#x000a0;Types of Tumors</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Giant cell tumor</p>
          </list-item>
          <list-item>
            <p>Osteoblastoma</p>
          </list-item>
          <list-item>
            <p>Enchondroma</p>
          </list-item>
          <list-item>
            <p>Chondromyxoid fibroma</p>
          </list-item>
          <list-item>
            <p>Cortical desmoid</p>
          </list-item>
        </list>
        <p>
<bold>Infection</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Osteomyelitis</p>
          </list-item>
        </list>
        <p>
<bold>Trauma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fracture callus</p>
          </list-item>
        </list>
        <p>
<bold>Other</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Aneurysmal bone cyst</p>
          </list-item>
          <list-item>
            <p>Fibrous dysplasia&#x000a0;<xref ref-type="bibr" rid="article-99465.r33">[33]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-99465.s11" sec-type="Staging">
        <title>Staging</title>
        <p>Two staging systems, the TNM and Enneking systems, are used in primary bone cancer.</p>
        <p>
<bold>TNM System, American Joint Committee on Cancer&#x000a0;</bold>
</p>
        <p>This refers to the extent of tumor (T), spread to local lymph nodes (N), metastatic spread (M), and histological grade (G).<xref ref-type="bibr" rid="article-99465.r34">[34]</xref></p>
        <p>
<bold>Stage IA (T1 N0 M0 G1/GX)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>&#x000a0;</bold>&#x02264;8cm in size, with no lymph node or metastatic spread</p>
          </list-item>
          <list-item>
            <p>Low grade</p>
          </list-item>
        </list>
        <p>
<bold>Stage IB (T2 N0 M0 G1/GX, or T3 N0 M0 G1/GX)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x0003e;8cm in size (T2), with no lymph node or metastatic spread; low grade</p>
          </list-item>
          <list-item>
            <p>Cancer at more than 1 location in the same bone (T3), with no lymph node or metastatic spread; low grade</p>
          </list-item>
        </list>
        <p>
<bold>Stage IIA (T1 N0 M0 G2/G3)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x02264;8cm in size, with no lymph node or metastatic spread; high grade</p>
          </list-item>
        </list>
        <p>
<bold>Stage IIB (T2 N0 M0 G2/G3)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x0003e;8cm in size, with no lymph node or metastatic spread; high grade</p>
          </list-item>
        </list>
        <p>
<bold>Stage III (T3 N0 M0 G2/G3)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cancer at more than 1 location in the same bone, with no lymph node or metastatic spread; high grade</p>
          </list-item>
        </list>
        <p>
<bold>Stage IVA (Any T N0 M1a Any G)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Any size and maybe in multiple locations in the same bone, with no lymph node involvement.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Metastatic spread to the lungs (M1a); any grade</p>
          </list-item>
        </list>
        <p>
<bold>Stage IVB (Any T, N1, Any M, Any G, or Any T, Any N, M1b, Any G)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Any size; may be in more than 1 location in the same bone&#x000a0;</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Has spread to local lymph nodes (N1)</p>
              </list-item>
              <list-item>
                <p>May or may not have metastasized to distant organs; any grade</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Any size and maybe in more than 1 location in the same bone.&#x000a0;</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>May or may not have spread to local lymph nodes&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Metastatic spreads to distant sites like other bones, liver, or brain (M1b); any grade</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Enneking System</bold>
</p>
        <p>Refers to the histological grade (G), the extent of the tumor to the anatomical compartments of the body (T), and metastatic spread (M).<xref ref-type="bibr" rid="article-99465.r35">[35]</xref></p>
        <p>
<bold>Stage IA (G1 T1 M0)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Low grade, intra-compartmental, no metastasis</p>
          </list-item>
        </list>
        <p>
<bold>Stage IB (G1 T2 M0)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Low grade, extra compartmental, no metastasis</p>
          </list-item>
        </list>
        <p>
<bold>Stage IIA (G2 T1 M0)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>High grade, intra-compartmental, no metastasis</p>
          </list-item>
        </list>
        <p>
<bold>Stage IIB (G2 T2 M0)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>High grade, extra compartmental, no metastasis</p>
          </list-item>
        </list>
        <p>
<bold>Stage III (Any G, Any T, M1)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Any grade, any location, regional, or distant metastatic spread</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-99465.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of primary bone cancer is dependent on multiple factors, and no significant improvement is seen in 5-year survival over the past 25 years. In the United States, the National Cancer Institute shows that the overall 5-year survival rate is 66%, with studies suggesting lower rates in the United Kingdom.<xref ref-type="bibr" rid="article-99465.r12">[12]</xref></p>
        <p>When the disease is localized, osteosarcoma has a 10-year survival of 60% to 78%. This number falls to 20% to 30% in patients with metastatic disease at presentation, with other negative prognostic factors including axial or proximal extremity tumor location, increased tumor size, raised alkaline phosphatase or lactase dehydrogenase, increased age, pathological fracture, and poor response to neoadjuvant chemotherapy.<xref ref-type="bibr" rid="article-99465.r36">[36]</xref><xref ref-type="bibr" rid="article-99465.r37">[37]</xref><xref ref-type="bibr" rid="article-99465.r38">[38]</xref></p>
        <p>The most potent prognostic factor in chondrosarcoma is histological grade. Other identified factors are metastatic disease at presentation, increased age, and pelvic tumor location. 5-year survival in grade I chondrosarcoma is 83%, with only 53% of patients surviving to 5 years with grade I and II diseases.<xref ref-type="bibr" rid="article-99465.r5">[5]</xref><xref ref-type="bibr" rid="article-99465.r39">[39]</xref><xref ref-type="bibr" rid="article-99465.r40">[40]</xref>&#x000a0;Ewing sarcoma has a 5-year survival of 70% to 80% when the disease is localized. This number falls to 50% in patients with isolated pulmonary metastases and less than 30% in patients with any other metastatic disease at diagnosis. Other negative prognostic factors include pelvic tumor location, increased tumor size, and poor response to neoadjuvant or adjuvant chemotherapy treatment.<xref ref-type="bibr" rid="article-99465.r14">[14]</xref><xref ref-type="bibr" rid="article-99465.r41">[41]</xref></p>
      </sec>
      <sec id="article-99465.s13" sec-type="Complications">
        <title>Complications</title>
        <p>The complications of primary bone cancer include the following:</p>
        <p>
<bold>Tumor-Related Complications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pathological fracture</p>
          </list-item>
          <list-item>
            <p>Tumor recurrence</p>
          </list-item>
          <list-item>
            <p>Distant metastasis&#x000a0;<xref ref-type="bibr" rid="article-99465.r42">[42]</xref><xref ref-type="bibr" rid="article-99465.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Treatment-Related Complications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Surgery
<list list-type="bullet"><list-item><p>Surgical site or periprosthetic infection</p></list-item><list-item><p>Implant failure</p></list-item><list-item><p>Non-union/fracture of the biological implant</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Chemotherapy
<list list-type="bullet"><list-item><p>Short-term side effects include malaise, anemia, nausea, vomiting, and alopecia</p></list-item><list-item><p>Long-term side effects include cardiotoxicity, renal toxicity, hearing loss, and an increased risk of secondary malignancy</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Radiotherapy
<list list-type="bullet"><list-item><p>Side effects following radiation therapy are site-dependent, affecting the skin, pelvic organs, gastrointestinal tract, and lungs</p></list-item><list-item><p>Long-term, a small increased risk of developing a secondary malignancy exists&#x000a0;<xref ref-type="bibr" rid="article-99465.r43">[43]</xref><xref ref-type="bibr" rid="article-99465.r44">[44]</xref><xref ref-type="bibr" rid="article-99465.r45">[45]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-99465.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>The key points are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary bone cancer&#x000a0;is a rare malignancy derived from primitive mesenchymal cells.</p>
          </list-item>
          <list-item>
            <p>All patients presenting with unresolved bone pain should be assessed, and orthogonal plain film radiographs should be organized.</p>
          </list-item>
          <list-item>
            <p>MRI is the gold standard for assessing the extent of a local tumor.</p>
          </list-item>
          <list-item>
            <p>A multidisciplinary team should manage&#x000a0;primary bone cancer in a specialized bone cancer center.</p>
          </list-item>
          <list-item>
            <p>Surgical excision remains the mainstay of treatment for primary bone cancer, with chemotherapy and radiotherapy often used as adjuncts.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-99465.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Primary bone cancer should be managed by a multidisciplinary team. The team should include clinicians from radiology, histopathology, oncology, and orthopedics. Radiologists and pathologists interpret initial imaging and tissue samples,&#x000a0;indicating&#x000a0;a definitive diagnosis&#x000a0;and leading to&#x000a0;surgical planning.</p>
        <p>Oncologists determine the most appropriate neoadjuvant and adjuvant chemotherapy protocols and arrange follow-up and surveillance. Orthopedics plan and perform surgical resection of the tumor, along with any initial or future reconstruction. Other team members include nurses, physiotherapists, occupational therapists, prosthetists, dieticians, social workers, and counselors.<xref ref-type="bibr" rid="article-99465.r46">[46]</xref><xref ref-type="bibr" rid="article-99465.r47">[47]</xref></p>
      </sec>
      <sec id="article-99465.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=99465&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=99465">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/primary-bone-cancer/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=99465">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/99465/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=99465">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-99465.s17">
        <title>References</title>
        <ref id="article-99465.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kube</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Blattmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bielack</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kager</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kaatsch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sorg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kevric</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jabar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hallmen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sparber-Sauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klingebiel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koscielniak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dirksen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hecker-Nolting</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ger&#x000df;</surname>
                <given-names>JWO</given-names>
              </name>
            </person-group>
            <article-title>Secondary malignant neoplasms after bone and soft tissue sarcomas in children, adolescents, and young adults.</article-title>
            <source>Cancer</source>
            <year>2022</year>
            <month>May</month>
            <day>01</day>
            <volume>128</volume>
            <issue>9</issue>
            <fpage>1787</fpage>
            <page-range>1787-1800</page-range>
            <pub-id pub-id-type="pmid">35195899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hameed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mandelker</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Tumor Syndromes Predisposing to Osteosarcoma.</article-title>
            <source>Adv Anat Pathol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>217</fpage>
            <page-range>217-222</page-range>
            <pub-id pub-id-type="pmid">29668499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berrington de Gonzalez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kutsenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rajaraman</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Sarcoma risk after radiation exposure.</article-title>
            <source>Clin Sarcoma Res</source>
            <year>2012</year>
            <month>Oct</month>
            <day>04</day>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">23036235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hansen</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Seton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Merchant</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma in Paget's disease of bone.</article-title>
            <source>J Bone Miner Res</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>21 Suppl 2</volume>
            <fpage>P58</fpage>
            <page-range>P58-63</page-range>
            <pub-id pub-id-type="pmid">17229010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hogendoorn</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Dijkstra</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>van Rijswijk</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Krol</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Taminiau</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bov&#x000e9;e</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>The clinical approach towards chondrosarcoma.</article-title>
            <source>Oncologist</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>320</fpage>
            <page-range>320-9</page-range>
            <pub-id pub-id-type="pmid">18378543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerrand</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Athanasou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grimer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Morland</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Peake</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seddon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>J</given-names>
              </name>
              <collab>British Sarcoma Group</collab>
            </person-group>
            <article-title>UK guidelines for the management of bone sarcomas.</article-title>
            <source>Clin Sarcoma Res</source>
            <year>2016</year>
            <volume>6</volume>
            <fpage>7</fpage>
            <pub-id pub-id-type="pmid">27148438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirabello</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Troisi</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons.</article-title>
            <source>Int J Cancer</source>
            <year>2009</year>
            <month>Jul</month>
            <day>01</day>
            <volume>125</volume>
            <issue>1</issue>
            <fpage>229</fpage>
            <page-range>229-34</page-range>
            <pub-id pub-id-type="pmid">19330840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messerschmitt</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Abdul-Karim</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Greenfield</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Getty</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma.</article-title>
            <source>J Am Acad Orthop Surg</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>8</issue>
            <fpage>515</fpage>
            <page-range>515-27</page-range>
            <pub-id pub-id-type="pmid">19652033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morrow</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies.</article-title>
            <source>Crit Rev Oncog</source>
            <year>2015</year>
            <volume>20</volume>
            <issue>3-4</issue>
            <fpage>173</fpage>
            <page-range>173-97</page-range>
            <pub-id pub-id-type="pmid">26349415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayden</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma: basic science and clinical implications.</article-title>
            <source>Orthop Clin North Am</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">16311106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chow</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Chondrosarcoma: biology, genetics, and epigenetics.</article-title>
            <source>F1000Res</source>
            <year>2018</year>
            <volume>7</volume>
            <pub-id pub-id-type="pmid">30519452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McTiernan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vernon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Incidence and survival of malignant bone sarcomas in England 1979-2007.</article-title>
            <source>Int J Cancer</source>
            <year>2012</year>
            <month>Aug</month>
            <day>15</day>
            <volume>131</volume>
            <issue>4</issue>
            <fpage>E508</fpage>
            <page-range>E508-17</page-range>
            <pub-id pub-id-type="pmid">21913189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Paulussen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Randall</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Schuck</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teot</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Juergens</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Ewing's sarcoma family of tumors: current management.</article-title>
            <source>Oncologist</source>
            <year>2006</year>
            <month>May</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>503</fpage>
            <page-range>503-19</page-range>
            <pub-id pub-id-type="pmid">16720851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gr&#x000fc;newald</surname>
                <given-names>TGP</given-names>
              </name>
              <name>
                <surname>Cidre-Aranaz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Surdez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tomazou</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>de &#x000c1;lava</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kovar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sorensen</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Delattre</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dirksen</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Ewing sarcoma.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2018</year>
            <month>Jul</month>
            <day>05</day>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <pub-id pub-id-type="pmid">29977059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Siegal</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma: anatomic and histologic variants.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>125</volume>
            <issue>4</issue>
            <fpage>555</fpage>
            <page-range>555-81</page-range>
            <pub-id pub-id-type="pmid">16627266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Praag Veroniek</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Rueten-Budde</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dijkstra</surname>
                <given-names>PDS</given-names>
              </name>
              <collab>Study group Bone and Soft tissue tumours (WeBot)</collab>
              <name>
                <surname>Fiocco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van de Sande</surname>
                <given-names>MAJ</given-names>
              </name>
            </person-group>
            <article-title>Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas.</article-title>
            <source>Surg Oncol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>402</fpage>
            <page-range>402-408</page-range>
            <pub-id pub-id-type="pmid">30217294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphey</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Kransdorf</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Temple</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Gannon</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation.</article-title>
            <source>Radiographics</source>
            <year>2003</year>
            <season>Sep-Oct</season>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>1245</fpage>
            <page-range>1245-78</page-range>
            <pub-id pub-id-type="pmid">12975513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desai</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Jambhekar</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Pathology of Ewing's sarcoma/PNET: Current opinion and emerging concepts.</article-title>
            <source>Indian J Orthop</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>363</fpage>
            <page-range>363-8</page-range>
            <pub-id pub-id-type="pmid">20924475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giannoulis</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Gantsos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giotis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Paschos</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Vagionas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arnaoutoglou</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Pentheroudakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Xenakis</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Multiple recurrences and late metastasis of adamantinoma in the tibia: a case report.</article-title>
            <source>J Orthop Surg (Hong Kong)</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>420</fpage>
            <page-range>420-2</page-range>
            <pub-id pub-id-type="pmid">25550030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doyle</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone.</article-title>
            <source>Cancer</source>
            <year>2014</year>
            <month>Jun</month>
            <day>15</day>
            <volume>120</volume>
            <issue>12</issue>
            <fpage>1763</fpage>
            <page-range>1763-74</page-range>
            <pub-id pub-id-type="pmid">24648013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plant</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic work up and recognition of primary bone tumours: a review.</article-title>
            <source>EFORT Open Rev</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>1</volume>
            <issue>6</issue>
            <fpage>247</fpage>
            <page-range>247-253</page-range>
            <pub-id pub-id-type="pmid">28461955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kundu</surname>
                <given-names>ZS</given-names>
              </name>
            </person-group>
            <article-title>Classification, imaging, biopsy and staging of osteosarcoma.</article-title>
            <source>Indian J Orthop</source>
            <year>2014</year>
            <month>May</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>238</fpage>
            <page-range>238-46</page-range>
            <pub-id pub-id-type="pmid">24932027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amit</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Patro</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Elangovan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parathasarathy</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Role of dynamic MRI and clinical assessment in predicting histologic response to neoadjuvant chemotherapy in bone sarcomas.</article-title>
            <source>Am J Clin Oncol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>384</fpage>
            <page-range>384-90</page-range>
            <pub-id pub-id-type="pmid">23388556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quartuccio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wexler</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Baldari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cistaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;der</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Pediatric bone sarcoma: diagnostic performance of &#x000b9;&#x02078;F-FDG PET/CT versus conventional imaging for initial staging and follow-up.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>204</volume>
            <issue>1</issue>
            <fpage>153</fpage>
            <page-range>153-60</page-range>
            <pub-id pub-id-type="pmid">25539251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Endo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Surgical margins in the management of extremity soft tissue sarcoma.</article-title>
            <source>Chin Clin Oncol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>37</fpage>
            <pub-id pub-id-type="pmid">30173528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carrle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bielack</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Current strategies of chemotherapy in osteosarcoma.</article-title>
            <source>Int Orthop</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>445</fpage>
            <page-range>445-51</page-range>
            <pub-id pub-id-type="pmid">16896870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ibrahim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mercatali</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Amadori</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Bone and cancer: the osteoncology.</article-title>
            <source>Clin Cases Miner Bone Metab</source>
            <year>2013</year>
            <month>May</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-3</page-range>
            <pub-id pub-id-type="pmid">24133529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burgert</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Nesbit</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Garnsey</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Gehan</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vietti</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Cangir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tefft</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II.</article-title>
            <source>J Clin Oncol</source>
            <year>1990</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>9</issue>
            <fpage>1514</fpage>
            <page-range>1514-24</page-range>
            <pub-id pub-id-type="pmid">2099751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anninga</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fiocco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kroep</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Taminiau</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Hogendoorn</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Egeler</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?</article-title>
            <source>Eur J Cancer</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>47</volume>
            <issue>16</issue>
            <fpage>2431</fpage>
            <page-range>2431-45</page-range>
            <pub-id pub-id-type="pmid">21703851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smeland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mercuri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bertoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Longhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruggieri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alvegard</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Picci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Capanna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bernini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tienghi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wiebe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Comandone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hling</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Del Prever</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Brosj&#x000f6;</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bacci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saeter</surname>
                <given-names>G</given-names>
              </name>
              <collab>Italian and Scandinavian Sarcoma Groups</collab>
            </person-group>
            <article-title>Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Dec</month>
            <day>01</day>
            <volume>23</volume>
            <issue>34</issue>
            <fpage>8845</fpage>
            <page-range>8845-52</page-range>
            <pub-id pub-id-type="pmid">16246977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bacci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Palmerini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Staals</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Longhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barbieri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alberghini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ewing's sarcoma family tumors of the humerus: outcome of patients treated with radiotherapy, surgery or surgery and adjuvant radiotherapy.</article-title>
            <source>Radiother Oncol</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>383</fpage>
            <page-range>383-7</page-range>
            <pub-id pub-id-type="pmid">19576648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Indelicato</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Keole</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Shahlaee</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2008</year>
            <month>Nov</month>
            <day>01</day>
            <volume>72</volume>
            <issue>3</issue>
            <fpage>871</fpage>
            <page-range>871-7</page-range>
            <pub-id pub-id-type="pmid">18455323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheung</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yechoor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Behnia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Abadi</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Khodarahmi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Soltanolkotabi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shafiei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chalian</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Common Skeletal Neoplasms and Nonneoplastic Lesions at <sup>18</sup>F-FDG PET/CT.</article-title>
            <source>Radiographics</source>
            <year>2022</year>
            <season>Jan-Feb</season>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>250</fpage>
            <page-range>250-267</page-range>
            <pub-id pub-id-type="pmid">34919467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edge</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Compton</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.</article-title>
            <source>Ann Surg Oncol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1471</fpage>
            <page-range>1471-4</page-range>
            <pub-id pub-id-type="pmid">20180029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Enneking</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Spanier</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>A system for the surgical staging of musculoskeletal sarcoma.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>1980</year>
            <season>Nov-Dec</season>
            <issue>153</issue>
            <fpage>106</fpage>
            <page-range>106-20</page-range>
            <pub-id pub-id-type="pmid">7449206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wadhwa</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors.</article-title>
            <source>Indian J Orthop</source>
            <year>2014</year>
            <month>May</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-54</page-range>
            <pub-id pub-id-type="pmid">24932029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bacci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Longhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Briccoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Donati</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Paolis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Versari</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years.</article-title>
            <source>Tumori</source>
            <year>2004</year>
            <season>Sep-Oct</season>
            <volume>90</volume>
            <issue>5</issue>
            <fpage>478</fpage>
            <page-range>478-84</page-range>
            <pub-id pub-id-type="pmid">15656333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scully</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Ghert</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zurakowski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gebhardt</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Pathologic fracture in osteosarcoma : prognostic importance and treatment implications.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>84</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-57</page-range>
            <pub-id pub-id-type="pmid">11792779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fromm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baur-Melnyk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kn&#x000f6;sel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lindner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Birkenmaier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Roeder</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jansson</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>D&#x000fc;rr</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Survival and prognostic factors in conventional central chondrosarcoma.</article-title>
            <source>BMC Cancer</source>
            <year>2018</year>
            <month>Aug</month>
            <day>24</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>849</fpage>
            <pub-id pub-id-type="pmid">30143018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stevenson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Laitinen</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Parry</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Sumathi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Grimer</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Jeys</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>The role of surgical margins in chondrosarcoma.</article-title>
            <source>Eur J Surg Oncol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>9</issue>
            <fpage>1412</fpage>
            <page-range>1412-1418</page-range>
            <pub-id pub-id-type="pmid">29929901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaspar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Dirksen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Le Deley</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Kovar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grimer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Claude</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Delattre</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Paulussen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Picci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sundby Hall</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ladenstein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Michon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hjorth</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Luksch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Marec-B&#x000e9;rard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Craft</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Womer</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Juergens</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oberlin</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.</article-title>
            <source>J Clin Oncol</source>
            <year>2015</year>
            <month>Sep</month>
            <day>20</day>
            <volume>33</volume>
            <issue>27</issue>
            <fpage>3036</fpage>
            <page-range>3036-46</page-range>
            <pub-id pub-id-type="pmid">26304893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salunke</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Puhaindran</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Does a pathological fracture affect the prognosis in patients with osteosarcoma of the extremities?</article-title>
            <source>J Cancer Res Ther</source>
            <year>2015</year>
            <season>Oct-Dec</season>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>1043</fpage>
            <pub-id pub-id-type="pmid">26881673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiwari</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Current concepts in surgical treatment of osteosarcoma.</article-title>
            <source>J Clin Orthop Trauma</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-9</page-range>
            <pub-id pub-id-type="pmid">25983449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kamar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Progress in the chemotherapeutic treatment of osteosarcoma.</article-title>
            <source>Oncol Lett</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>6228</fpage>
            <page-range>6228-6237</page-range>
            <pub-id pub-id-type="pmid">30405759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tamburini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Luksch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fagioli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bacci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006).</article-title>
            <source>Cancer</source>
            <year>2012</year>
            <month>Oct</month>
            <day>15</day>
            <volume>118</volume>
            <issue>20</issue>
            <fpage>5050</fpage>
            <page-range>5050-9</page-range>
            <pub-id pub-id-type="pmid">22415578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stitzlein</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Wojcik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sebro</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Balamuth</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Team Approach: Osteosarcoma of the Distal Part of the Femur in Adolescents.</article-title>
            <source>JBJS Rev</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>e5</fpage>
            <pub-id pub-id-type="pmid">29278618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-99465.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Biermann</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chugh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lucas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hasen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The multidisciplinary management of bone and soft tissue sarcoma: an essential organizational framework.</article-title>
            <source>J Multidiscip Healthc</source>
            <year>2015</year>
            <volume>8</volume>
            <fpage>109</fpage>
            <page-range>109-15</page-range>
            <pub-id pub-id-type="pmid">25733913</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
